Hormonal
Discontinuation of GLP-1 RA therapy is associated with significant weight regain, loss of cardiorenal protection, and an increased risk of Major Adverse Cardiovascular Events (MACE).
If you stop taking your GLP-1 medication (like Ozempic or Wegovy), you are likely to regain much of the weight you lost. More importantly, studies show that stopping these drugs increases your risk of heart attacks, strokes, and other cardiovascular events. If you are considering stopping due to side effects, talk to your doctor about adjusting the dose or switching medications rather than stopping abruptly, to protect your heart and maintain your weight loss.
The investigators reported that discontinuation of therapy was independently associated with a significant increase in the risk of developing a major adverse cardiovascular event (MACE)
Why this rating
Supported by retrospective cohort studies and randomized trials (STEP-5, etc.).
Source
The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review
Janet B. McGill et al. · Diabetes Therapy · 2024
DOI 10.1007/s13300-024-01569-8
More from this paper
- Combining GLP-1 RAs with basal insulin provides superior glycemic management and cardiorenal protection compared to using either therapy alone, while mitigating the side effects of high-dose GLP-1 RAs.Strong
- GLP-1 receptor agonists (GLP-1 RAs) are dependent on residual beta-cell function and insulin availability, meaning that as Type 2 Diabetes progresses and beta-cell function declines, GLP-1 RAs lose efficacy and patients eventually require insulin therapy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →